These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29914746)

  • 1. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
    Lee AC; Jones AL
    Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
    Plant AJ; Dunn A; Porter RJ
    Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
    Katzenstein TL; Faurholt-Jepsen D; Qvist T; Jensen PØ; Pressler T; Johansen HK; Kolpen M
    APMIS; 2023 Aug; 131(8):419-425. PubMed ID: 37294911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis.
    Lim SZP; Fitzgerald DA
    Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
    Marner M; Kolberg L; Horst J; Böhringer N; Hübner J; Kresna IDM; Liu Y; Mettal U; Wang L; Meyer-Bühn M; Mihajlovic S; Kappler M; Schäberle TF; von Both U
    Microbiol Spectr; 2023 Feb; 11(1):e0443722. PubMed ID: 36692293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
    Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
    Royer G; Fourreau F; Boulanger B; Mercier-Darty M; Ducellier D; Cizeau F; Potron A; Podglajen I; Mongardon N; Decousser JW
    J Hosp Infect; 2020 Jan; 104(1):33-39. PubMed ID: 31369808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Gherardi G; Linardos G; Pompilio A; Fiscarelli E; Di Bonaventura G
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):297-303. PubMed ID: 30803726
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.